financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Hold Opinion On Shares Of Westrock Company
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Hold Opinion On Shares Of Westrock Company
May 3, 2024 9:41 AM

12:15 PM EDT, 05/03/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We increase our 12-month target price by $14 to $53, which assumes an EV/EBITDA multiple of 6.7x our FY 25 (Sep.) EBITDA estimate, a premium to WRK's three-year average forward EV/EBITDA of 6.1x but a discount to peers, which are trading at an average forward EV/EBITDA of 8.0x. We raise our FY 24 EPS estimate by $0.09 to $2.15 and our FY 25 EPS forecast by $0.84 to $3.40. WRK posted FQ2 adj. EPS of $0.39 vs. $0.77, $0.10 above consensus, with sales that missed consensus by 1%. One of the major highlights from FQ2 is the significant cost savings achieved with self-help efficiency programs; $370 million in cost savings have been achieved YTD and WRK should easily exceed its previous guidance of $300-$400 million in savings. Unfortunately, the cost savings of $164 million Y/Y during FQ2 didn't fully offset the $257 million Y/Y headwind from unfavorable price/mix and adj. EBITDA fell 22% Y/Y to $618 million. We are encouraged by positive momentum in corrugated box shipments, improving to 3.3% Y/Y growth in March.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Copyright 2023-2026 - www.financetom.com All Rights Reserved